HYDRA is a fully resorbable vascular access graft that is replaced by healthy vascular tissue. Addressing the problems experienced with standard vascular grafts.
Two of the primary methods of vascular access for hemodialysis patients are the arteriovenous (AV) fistula and AV graft.
Failure is reported in up to 40% of AV fistula cases
- Early thrombosis or lack of maturation are often causes of failure
- This procedure may not be an option for patients that smoke or have diabetes.
- More than half of the grafts placed will fail after approximately six months, rising to 95% after two years
- Prone to stenosis, neointimal hyperplasia, rejection, infection, and graft failure
HYDRA is a fully resorbable vascular access graft that is replaced by healthy vascular tissue. Addressing the problems experienced with current vascular grafts.
There are no fully resorbable synthetic vascular conduit products currently on the market. Biologic devices are more difficult to manufacture, cost much more, carry a risk of an immune reaction, and face a significant regulatory hurdle.